Nucleic acid amplification technologies are used for the rapid and accurate diagnosis of chronic and infectious diseases. The nucleic acid amplification is one of the important tool for wide aspects of life science technologies including, clinical medicine development, diagnosis of infectious diseases, and gene cloning.
Highlights
The global Nucleic Acid Amplification Detection and Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nucleic Acid Amplification Detection and Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nucleic Acid Amplification Detection and Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nucleic Acid Amplification Detection and Diagnostics in Hospital and Clinics is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nucleic Acid Amplification Detection and Diagnostics include BD, BioMerieux SA, BIO-RAD LABORATORIES INC., THERMO FISHER SCIENTIFIC INC., Illumina, Inc., Danaher, QIAGEN, Abbott and Meridian Bioscience, Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Amplification Detection and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Amplification Detection and Diagnostics.
The Nucleic Acid Amplification Detection and Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nucleic Acid Amplification Detection and Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid Amplification Detection and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
BD
BioMerieux SA
BIO-RAD LABORATORIES INC.
THERMO FISHER SCIENTIFIC INC.
Illumina, Inc.
Danaher
QIAGEN
Abbott
Meridian Bioscience, Inc.
F. Hoffmann-La Roche Ltd.
PreAnalytiX
Eiken Chemical
Lucigen
OptiGene
NEB
Quidel Corporation
Promega
Hologic
Ustar
Grifols
Nugen
Segment by Type
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Isothermal Amplification Technology
Direct Nucleic Acid Detection
CRISPR-Cas9
Segment by Application
Hospital and Clinics
Diagnostic Centers
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Amplification Detection and Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Amplification Detection and Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next Generation Sequencing (NGS)
1.2.4 Isothermal Amplification Technology
1.2.5 Direct Nucleic Acid Detection
1.2.6 CRISPR-Cas9
1.3 Market by Application
1.3.1 Global Nucleic Acid Amplification Detection and Diagnostics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital and Clinics
1.3.3 Diagnostic Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Amplification Detection and Diagnostics Market Perspective (2018-2029)
2.2 Nucleic Acid Amplification Detection and Diagnostics Growth Trends by Region
2.2.1 Global Nucleic Acid Amplification Detection and Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid Amplification Detection and Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Nucleic Acid Amplification Detection and Diagnostics Forecasted Market Size by Region (2024-2029)
2.3 Nucleic Acid Amplification Detection and Diagnostics Market Dynamics
2.3.1 Nucleic Acid Amplification Detection and Diagnostics Industry Trends
2.3.2 Nucleic Acid Amplification Detection and Diagnostics Market Drivers
2.3.3 Nucleic Acid Amplification Detection and Diagnostics Market Challenges
2.3.4 Nucleic Acid Amplification Detection and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Amplification Detection and Diagnostics Players by Revenue
3.1.1 Global Top Nucleic Acid Amplification Detection and Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Nucleic Acid Amplification Detection and Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Nucleic Acid Amplification Detection and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid Amplification Detection and Diagnostics Revenue
3.4 Global Nucleic Acid Amplification Detection and Diagnostics Market Concentration Ratio
3.4.1 Global Nucleic Acid Amplification Detection and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Amplification Detection and Diagnostics Revenue in 2022
3.5 Nucleic Acid Amplification Detection and Diagnostics Key Players Head office and Area Served
3.6 Key Players Nucleic Acid Amplification Detection and Diagnostics Product Solution and Service
3.7 Date of Enter into Nucleic Acid Amplification Detection and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Amplification Detection and Diagnostics Breakdown Data by Type
4.1 Global Nucleic Acid Amplification Detection and Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Nucleic Acid Amplification Detection and Diagnostics Forecasted Market Size by Type (2024-2029)
5 Nucleic Acid Amplification Detection and Diagnostics Breakdown Data by Application
5.1 Global Nucleic Acid Amplification Detection and Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid Amplification Detection and Diagnostics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid Amplification Detection and Diagnostics Market Size (2018-2029)
6.2 North America Nucleic Acid Amplification Detection and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2018-2023)
6.4 North America Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Amplification Detection and Diagnostics Market Size (2018-2029)
7.2 Europe Nucleic Acid Amplification Detection and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2018-2023)
7.4 Europe Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Amplification Detection and Diagnostics Market Size (2018-2029)
8.2 Asia-Pacific Nucleic Acid Amplification Detection and Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nucleic Acid Amplification Detection and Diagnostics Market Size by Region (2018-2023)
8.4 Asia-Pacific Nucleic Acid Amplification Detection and Diagnostics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Amplification Detection and Diagnostics Market Size (2018-2029)
9.2 Latin America Nucleic Acid Amplification Detection and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2018-2023)
9.4 Latin America Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Amplification Detection and Diagnostics Market Size (2018-2029)
10.2 Middle East & Africa Nucleic Acid Amplification Detection and Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2018-2023)
10.4 Middle East & Africa Nucleic Acid Amplification Detection and Diagnostics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BD
11.1.1 BD Company Detail
11.1.2 BD Business Overview
11.1.3 BD Nucleic Acid Amplification Detection and Diagnostics Introduction
11.1.4 BD Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.1.5 BD Recent Development
11.2 BioMerieux SA
11.2.1 BioMerieux SA Company Detail
11.2.2 BioMerieux SA Business Overview
11.2.3 BioMerieux SA Nucleic Acid Amplification Detection and Diagnostics Introduction
11.2.4 BioMerieux SA Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.2.5 BioMerieux SA Recent Development
11.3 BIO-RAD LABORATORIES INC.
11.3.1 BIO-RAD LABORATORIES INC. Company Detail
11.3.2 BIO-RAD LABORATORIES INC. Business Overview
11.3.3 BIO-RAD LABORATORIES INC. Nucleic Acid Amplification Detection and Diagnostics Introduction
11.3.4 BIO-RAD LABORATORIES INC. Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.3.5 BIO-RAD LABORATORIES INC. Recent Development
11.4 THERMO FISHER SCIENTIFIC INC.
11.4.1 THERMO FISHER SCIENTIFIC INC. Company Detail
11.4.2 THERMO FISHER SCIENTIFIC INC. Business Overview
11.4.3 THERMO FISHER SCIENTIFIC INC. Nucleic Acid Amplification Detection and Diagnostics Introduction
11.4.4 THERMO FISHER SCIENTIFIC INC. Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.4.5 THERMO FISHER SCIENTIFIC INC. Recent Development
11.5 Illumina, Inc.
11.5.1 Illumina, Inc. Company Detail
11.5.2 Illumina, Inc. Business Overview
11.5.3 Illumina, Inc. Nucleic Acid Amplification Detection and Diagnostics Introduction
11.5.4 Illumina, Inc. Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.5.5 Illumina, Inc. Recent Development
11.6 Danaher
11.6.1 Danaher Company Detail
11.6.2 Danaher Business Overview
11.6.3 Danaher Nucleic Acid Amplification Detection and Diagnostics Introduction
11.6.4 Danaher Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.6.5 Danaher Recent Development
11.7 QIAGEN
11.7.1 QIAGEN Company Detail
11.7.2 QIAGEN Business Overview
11.7.3 QIAGEN Nucleic Acid Amplification Detection and Diagnostics Introduction
11.7.4 QIAGEN Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.7.5 QIAGEN Recent Development
11.8 Abbott
11.8.1 Abbott Company Detail
11.8.2 Abbott Business Overview
11.8.3 Abbott Nucleic Acid Amplification Detection and Diagnostics Introduction
11.8.4 Abbott Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.8.5 Abbott Recent Development
11.9 Meridian Bioscience, Inc.
11.9.1 Meridian Bioscience, Inc. Company Detail
11.9.2 Meridian Bioscience, Inc. Business Overview
11.9.3 Meridian Bioscience, Inc. Nucleic Acid Amplification Detection and Diagnostics Introduction
11.9.4 Meridian Bioscience, Inc. Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.9.5 Meridian Bioscience, Inc. Recent Development
11.10 F. Hoffmann-La Roche Ltd.
11.10.1 F. Hoffmann-La Roche Ltd. Company Detail
11.10.2 F. Hoffmann-La Roche Ltd. Business Overview
11.10.3 F. Hoffmann-La Roche Ltd. Nucleic Acid Amplification Detection and Diagnostics Introduction
11.10.4 F. Hoffmann-La Roche Ltd. Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.10.5 F. Hoffmann-La Roche Ltd. Recent Development
11.11 PreAnalytiX
11.11.1 PreAnalytiX Company Detail
11.11.2 PreAnalytiX Business Overview
11.11.3 PreAnalytiX Nucleic Acid Amplification Detection and Diagnostics Introduction
11.11.4 PreAnalytiX Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.11.5 PreAnalytiX Recent Development
11.12 Eiken Chemical
11.12.1 Eiken Chemical Company Detail
11.12.2 Eiken Chemical Business Overview
11.12.3 Eiken Chemical Nucleic Acid Amplification Detection and Diagnostics Introduction
11.12.4 Eiken Chemical Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.12.5 Eiken Chemical Recent Development
11.13 Lucigen
11.13.1 Lucigen Company Detail
11.13.2 Lucigen Business Overview
11.13.3 Lucigen Nucleic Acid Amplification Detection and Diagnostics Introduction
11.13.4 Lucigen Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.13.5 Lucigen Recent Development
11.14 OptiGene
11.14.1 OptiGene Company Detail
11.14.2 OptiGene Business Overview
11.14.3 OptiGene Nucleic Acid Amplification Detection and Diagnostics Introduction
11.14.4 OptiGene Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.14.5 OptiGene Recent Development
11.15 NEB
11.15.1 NEB Company Detail
11.15.2 NEB Business Overview
11.15.3 NEB Nucleic Acid Amplification Detection and Diagnostics Introduction
11.15.4 NEB Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.15.5 NEB Recent Development
11.16 Quidel Corporation
11.16.1 Quidel Corporation Company Detail
11.16.2 Quidel Corporation Business Overview
11.16.3 Quidel Corporation Nucleic Acid Amplification Detection and Diagnostics Introduction
11.16.4 Quidel Corporation Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.16.5 Quidel Corporation Recent Development
11.17 Promega
11.17.1 Promega Company Detail
11.17.2 Promega Business Overview
11.17.3 Promega Nucleic Acid Amplification Detection and Diagnostics Introduction
11.17.4 Promega Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.17.5 Promega Recent Development
11.18 Hologic
11.18.1 Hologic Company Detail
11.18.2 Hologic Business Overview
11.18.3 Hologic Nucleic Acid Amplification Detection and Diagnostics Introduction
11.18.4 Hologic Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.18.5 Hologic Recent Development
11.19 Ustar
11.19.1 Ustar Company Detail
11.19.2 Ustar Business Overview
11.19.3 Ustar Nucleic Acid Amplification Detection and Diagnostics Introduction
11.19.4 Ustar Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.19.5 Ustar Recent Development
11.20 Grifols
11.20.1 Grifols Company Detail
11.20.2 Grifols Business Overview
11.20.3 Grifols Nucleic Acid Amplification Detection and Diagnostics Introduction
11.20.4 Grifols Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.20.5 Grifols Recent Development
11.21 Nugen
11.21.1 Nugen Company Detail
11.21.2 Nugen Business Overview
11.21.3 Nugen Nucleic Acid Amplification Detection and Diagnostics Introduction
11.21.4 Nugen Revenue in Nucleic Acid Amplification Detection and Diagnostics Business (2018-2023)
11.21.5 Nugen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
BD
BioMerieux SA
BIO-RAD LABORATORIES INC.
THERMO FISHER SCIENTIFIC INC.
Illumina, Inc.
Danaher
QIAGEN
Abbott
Meridian Bioscience, Inc.
F. Hoffmann-La Roche Ltd.
PreAnalytiX
Eiken Chemical
Lucigen
OptiGene
NEB
Quidel Corporation
Promega
Hologic
Ustar
Grifols
Nugen
听
听
*If Applicable.
